Comprehensive Stock Comparison
Compare Coherus Oncology, Inc. (CHRS) vs Incyte Corporation (INCY) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | INCY | 21.2% revenue growth vs CHRS's 3.8% |
| Value | CHRS | Lower P/E (6.7x vs 13.4x) |
| Quality / Margins | CHRS | 185.4% net margin vs INCY's 25.0% |
| Stability / Safety | INCY | Beta 0.61 vs CHRS's 1.33 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | CHRS | +50.5% vs INCY's +37.8% |
| Efficiency (ROA) | CHRS | 30.0% ROA vs INCY's 18.5%, ROIC -85.3% vs 51.1% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Coherus Oncology is a biopharmaceutical company that develops and commercializes cancer immunotherapies and biosimilars. It generates revenue primarily from sales of its oncology biosimilars — including UDENYCA (a Neulasta biosimilar) and CIMERLI (a Lucentis biosimilar) — along with its novel immunotherapy LOQTORZI, with oncology products driving the majority of sales. The company's competitive advantage lies in its dual focus on lower-cost biosimilars that expand patient access and novel immunotherapies that target specific cancer pathways.
Incyte is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics for oncology and inflammatory diseases. It generates revenue primarily from sales of its flagship drug JAKAFI (ruxolitinib) for myelofibrosis and polycythemia vera — which accounts for the vast majority of its revenue — along with newer oncology products like PEMAZYRE and ICLUSIG. The company's moat lies in its deep expertise in kinase inhibition — particularly JAK inhibitors — and its established commercial infrastructure for hematology-oncology products.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
INCY leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). CHRS leads in 1 (Valuation Metrics).
Financial Metrics (TTM)
INCY is the larger business by revenue, generating $5.1B annually — 61.5x CHRS's $84M. CHRS is the more profitable business, keeping 185.4% of every revenue dollar as net income compared to INCY's 25.0%. On growth, INCY holds the edge at +27.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CHRSCoherus Oncology,… | INCYIncyte Corporation |
|---|---|---|
| RevenueTrailing 12 months | $84M | $5.1B |
| EBITDAEarnings before interest/tax | -$173M | $1.4B |
| Net IncomeAfter-tax profit | $155M | $1.3B |
| Free Cash FlowCash after capex | -$90M | $1.4B |
| Gross MarginGross profit ÷ Revenue | +47.8% | +91.8% |
| Operating MarginEBIT ÷ Revenue | -2.1% | +26.4% |
| Net MarginNet income ÷ Revenue | +185.4% | +25.0% |
| FCF MarginFCF ÷ Revenue | -107.9% | +26.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | -83.7% | +27.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.3% | +43.1% |
Valuation Metrics
At 6.7x trailing earnings, CHRS trades at a 58% valuation discount to INCY's 15.8x P/E.
| Metric | CHRSCoherus Oncology,… | INCYIncyte Corporation |
|---|---|---|
| Market CapShares × price | $194M | $20.1B |
| Enterprise ValueMkt cap + debt − cash | $338M | $17.1B |
| Trailing P/EPrice ÷ TTM EPS | 6.68x | 15.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 13.40x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 11.89x |
| Price / SalesMarket cap ÷ Revenue | 0.73x | 3.91x |
| Price / BookPrice ÷ Book value/share | — | 3.93x |
| Price / FCFMarket cap ÷ FCF | — | 14.84x |
Profitability & Efficiency
CHRS delivers a 176.6% return on equity — every $100 of shareholder capital generates $177 in annual profit, vs $25 for INCY. On the Piotroski fundamental quality scale (0–9), INCY scores 7/9 vs CHRS's 5/9, reflecting strong financial health.
| Metric | CHRSCoherus Oncology,… | INCYIncyte Corporation |
|---|---|---|
| ROE (TTM)Return on equity | +176.6% | +24.9% |
| ROA (TTM)Return on assets | +30.0% | +18.5% |
| ROICReturn on invested capital | -85.3% | +51.1% |
| ROCEReturn on capital employed | -48.2% | +29.0% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 |
| Debt / EquityFinancial leverage | — | 0.01x |
| Net DebtTotal debt minus cash | $144M | -$3.0B |
| Cash & Equiv.Liquid assets | $126M | $3.1B |
| Total DebtShort + long-term debt | $270M | $69M |
| Interest CoverageEBIT ÷ Interest expense | -14.50x | 686.52x |
Total Returns (with DRIP)
A $10,000 investment in INCY five years ago would be worth $12,718 today (with dividends reinvested), compared to $1,042 for CHRS. Over the past 12 months, CHRS leads with a +50.5% total return vs INCY's +37.8%. The 3-year compound annual growth rate (CAGR) favors INCY at 9.6% vs CHRS's -37.3% — a key indicator of consistent wealth creation.
| Metric | CHRSCoherus Oncology,… | INCYIncyte Corporation |
|---|---|---|
| YTD ReturnYear-to-date | +21.9% | -0.1% |
| 1-Year ReturnPast 12 months | +50.5% | +37.8% |
| 3-Year ReturnCumulative with dividends | -75.3% | +31.6% |
| 5-Year ReturnCumulative with dividends | -89.6% | +27.2% |
| 10-Year ReturnCumulative with dividends | -88.2% | +37.8% |
| CAGR (3Y)Annualised 3-year return | -37.3% | +9.6% |
Risk & Volatility
INCY is the less volatile stock with a 0.61 beta — it tends to amplify market swings less than CHRS's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INCY currently trades 90.2% from its 52-week high vs CHRS's 63.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CHRSCoherus Oncology,… | INCYIncyte Corporation |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.33x | 0.61x |
| 52-Week HighHighest price in past year | $2.62 | $112.29 |
| 52-Week LowLowest price in past year | $0.71 | $53.56 |
| % of 52W HighCurrent price vs 52-week peak | +63.8% | +90.2% |
| RSI (14)Momentum oscillator 0–100 | 44.1 | 44.9 |
| Avg Volume (50D)Average daily shares traded | 2.6M | 1.6M |
Analyst Outlook
Wall Street rates CHRS as "Buy" and INCY as "Buy". Consensus price targets imply 260.5% upside for CHRS (target: $6) vs 7.5% for INCY (target: $109).
| Metric | CHRSCoherus Oncology,… | INCYIncyte Corporation |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $6.02 | $108.90 |
| # AnalystsCovering analysts | 16 | 44 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Coherus Oncology, I… (CHRS) | 100 | 10.48 | -89.5% |
| Incyte Corporation (INCY) | 100 | 129.86 | +29.9% |
Incyte Corporation (INCY) returned +27% over 5 years vs Coherus Oncology, I… (CHRS)'s -90%. A $10,000 investment in INCY 5 years ago would be worth $12,718 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Coherus Oncology, I… (CHRS) | $190M | $267M | +40.4% |
| Incyte Corporation (INCY) | $1.1B | $5.1B | +365.0% |
Incyte Corporation's revenue grew from $1.1B (2016) to $5.1B (2025) — a 18.6% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Coherus Oncology, I… (CHRS) | -67.0% | 10.7% | +115.9% |
| Incyte Corporation (INCY) | 9.4% | 25.0% | +165.5% |
Incyte Corporation's net margin went from 9% (2016) to 25% (2025).
Chart 4P/E Ratio History — 8 Years
| Stock | 2018 | 2025 | Change |
|---|---|---|---|
| Coherus Oncology, I… (CHRS) | 14.6 | 5.5 | -62.3% |
| Incyte Corporation (INCY) | 124.7 | 15.4 | -87.7% |
Coherus Oncology, Inc. has traded in a 6x–15x P/E range over 3 years; current trailing P/E is ~7x. Incyte Corporation has traded in a 15x–461x P/E range over 7 years; current trailing P/E is ~16x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Coherus Oncology, I… (CHRS) | -3.04 | 0.25 | +108.2% |
| Incyte Corporation (INCY) | 0.54 | 6.41 | +1087.0% |
Incyte Corporation's EPS grew from $0.54 (2016) to $6.41 (2025) — a 32% CAGR.
Chart 6Free Cash Flow — 5 Years
Coherus Oncology, Inc. generated $-20M FCF in 2024 (+47% vs 2021). Incyte Corporation generated $1B FCF in 2025 (+138% vs 2021).
CHRS vs INCY: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CHRS or INCY a better buy right now?
Coherus Oncology, Inc. (CHRS) offers the better valuation at 6.7x trailing P/E, making it the more compelling value choice. Analysts rate Coherus Oncology, Inc. (CHRS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CHRS or INCY?
On trailing P/E, Coherus Oncology, Inc. (CHRS) is the cheapest at 6.7x versus Incyte Corporation at 15.8x.
03Which is the better long-term investment — CHRS or INCY?
Over the past 5 years, Incyte Corporation (INCY) delivered a total return of +27.2%, compared to -89.6% for Coherus Oncology, Inc. (CHRS). A $10,000 investment in INCY five years ago would be worth approximately $13K today (assuming dividends reinvested). Over 10 years, the gap is even starker: INCY returned +37.8% versus CHRS's -88.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CHRS or INCY?
By beta (market sensitivity over 5 years), Incyte Corporation (INCY) is the lower-risk stock at 0.61β versus Coherus Oncology, Inc.'s 1.33β — meaning CHRS is approximately 118% more volatile than INCY relative to the S&P 500.
05Which has better profit margins — CHRS or INCY?
Incyte Corporation (INCY) is the more profitable company, earning 25.0% net margin versus 10.7% for Coherus Oncology, Inc. — meaning it keeps 25.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INCY leads at 26.1% versus -41.8% for CHRS. At the gross margin level — before operating expenses — INCY leads at 91.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CHRS or INCY more undervalued right now?
Analyst consensus price targets imply the most upside for CHRS: 260.5% to $6.02.
07Which pays a better dividend — CHRS or INCY?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is CHRS or INCY better for a retirement portfolio?
For long-horizon retirement investors, Incyte Corporation (INCY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.61)). Both have compounded well over 10 years (INCY: +37.8%, CHRS: -88.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CHRS and INCY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.